3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Small Cell Lung Carcinoma
156
Lung Neoplasms
99
Carcinoma, Non-Small-Cell Lung
61
Extensive Stage Small Cell Lung Cancer
10
Adenocarcinoma of Lung
7
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Carcinoma, Small Cell
5
Adenocarcinoma, Bronchiolo-Alveolar
5
Small Cell Lung Cancer Extensive Stage
4
Drug-Related Side Effects and Adverse Reactions
4
Small Cell Lung Cancer Limited Stage
3
SCLC, Extensive Stage
3
SCLC
3
Recurrence
3
Radiation Injuries
3
Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Thymoma
2
Testicular Neoplasms
2
Testicular Germ Cell Tumor
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
SCLC,Extensive Stage
2
Ovarian Neoplasms
2
Melanoma
2
Limited Stage Small Cell Lung Cancer
2
Kidney Neoplasms
2
Extensive Small Cell Lung Cancer
2
Carcinoma, Neuroendocrine
2
Breast Neoplasms
2
Interventions
Cisplatin
8
Carboplatin
8
Bevacizumab
8
Pleurodesis
7
Talc
6
Paclitaxel
6
Docetaxel
5
Povidone-Iodine
4
Doxycycline
4
Thoracoscopy
3
Taxes
3
Gemcitabine
3
Drug Therapy
3
Chest Tubes
3
aldesleukin
2
Zoledronic Acid
2
Trastuzumab
2
Thoracentesis
2
Surveys and Questionnaires
2
Sodium Chloride
2
Silver Nitrate
2
Pharmaceutical Preparations
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Interleukin-2
2
High-Energy Shock Waves
2
Fluorodeoxyglucose F18
2
Fentanyl
2
Erlotinib Hydrochloride
2
Cetuximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pleural Effusion, Malignant
×
Etoposide
×
Thoracic
×
Clear all
NCT00791154
2024-08-23
SCLC
NantCell, Inc.
Phase 1/2
Terminated
213 enrolled
16 charts